接受18F-FDG-PET检查的肿瘤患者COVID-19疫苗接种率频率与时间演变
该研究评估了瑞士肿瘤队列中COVID-19疫苗接种的时间演变。研究纳入2021年2月至9月期间接受肿瘤18F-FDG PET/CT检查的患者(n=2613),获取其COVID-19完全疫苗接种史(至少两剂疫苗),并与瑞士联邦公共卫生局年龄匹配的国家数据比较接种率。结果显示完全接种率稳步上升,2021年9月达到81%;肿瘤队列接种比例初期高于年龄匹配的瑞士一般人群,研究期末趋于接近。检查月份是接种率的唯一显著预测因素(p<0.001)。
要点
- 2021年2月至9月,肿瘤队列COVID-19完全疫苗接种率稳步上升,9月达81%。
- 肿瘤队列接种比例初期高于年龄匹配的瑞士一般人群,研究期末趋于接近。
- 检查月份是接种率的唯一显著预测因素(p<0.001)。
核心结论
- 瑞士肿瘤队列COVID-19疫苗接种率从2021年2月至9月稳步上升。
- 与年龄匹配的一般人群相比,肿瘤队列接种率初期较高,研究期末相似。
- 检查月份是接种率的唯一显著预测因素(p<0.001)。
研究设计与样本
- 研究纳入2021年2月至9月期间接受肿瘤18F-FDG PET/CT检查的患者(n=2613),获取其COVID-19完全疫苗接种史(至少两剂疫苗)。
- 将肿瘤队列接种率与瑞士联邦公共卫生局年龄匹配的国家数据进行比较。
- 通过拟合广义线性模型分析接种率时间演变的亚组差异,并由性别、肿瘤诊断和检查月份之间的显著交互作用确定。
主要发现
- 完全疫苗接种率稳步上升,2021年9月达到81%。
- 肿瘤队列中接种疫苗的患者比例初期较高,研究期末接近年龄匹配的瑞士一般人群中的比例。
- 检查月份是接种率的唯一显著预测因素(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the temporal evolution of vaccination against COVID-19 in a Swiss oncological cohort. METHODS: History of complete vaccination (i.e. at least two vaccine doses) against COVID-19 of patients undergoing oncological 18F-FDG PET/CT between February and September 2021 (n = 2613) was taken. Vaccination rate was compared with age-matched national data from the Swiss Federal Office of Public Health. Subgroup differences in temporal evolution of vaccination rate were analyzed by fitting a generalized linear model and determined by significant interaction between, sex, oncological diagnosis, and month of examination. RESULTS: Rate of complete vaccination against COVID-19 steadily increased and reached 81 % in September 2021. The fraction of vaccinated patients in the oncological cohort was higher in the beginning and approached the fraction in the age-matched general Swiss population at the end of the study period. Month of exam (p < 0.001) was the only significant predictor of the vaccination rate. CONCLUSION: Vaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021. Compared to the age-matched general population it was higher in the beginning and similar by the end of the study period. Ethics approval: Trial registration: BASEC 2021-00444, Ethikkommission Zürich (Cantonal Ethics Committee Zurich), Switzerland, registered February 24th 2021.
引用
- Skawran S, Schiesser H, Maurer A, et al. Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET. Vaccine. 2022. PMID: 36372666. doi:10.1016/j.vaccine.2022.10.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。